Advertisement

Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study

      Highlights

      • A 40% discordance was identified between surgeon and CT imaging with respect to residual disease.
      • The most frequently identified areas of discordance include the retroperitoneum and upper abdomen.
      • Objective measures of residual disease volume should be explored.

      Abstract

      Purpose

      We sought to determine the level of concordance among surgeons' assessment of residual disease (RD) and pre-treatment computed tomography (CT) findings among women who underwent optimal surgical cytoreduction for advanced stage ovarian cancer.

      Methods

      This is a post-trial ad hoc analysis of a phase 3 randomized clinical trial evaluating the impact of bevacizumab in primary and maintenance therapy for patients with advanced stage ovarian cancer following surgical cytoreduction. All subjects underwent imaging of the chest/abdomen/pelvis to establish a post-surgical baseline prior to the initiation of chemotherapy. Information collected on trial was utilized to compare surgeon's operative assessment of RD, to pre-treatment imaging.

      Results

      Of 1873 enrolled patients, surgical outcome was described as optimal (RD ≤ 1 cm) in 639 subjects. Twelve patients were excluded as they did not have a baseline, pretreatment imaging, leaving 627 participants for analysis. The average interval from surgery to baseline scan was 26 days (range: 1–109). In 251 cases (40%), the post-operative scan was discordant with surgeon assessment, demonstrating RD > 1 cm in size. RD > 1 cm was most commonly identified in the right upper quadrant (28.4%), retroperitoneal para-aortic lymph nodes (RD > 1.5 cm; 28.2%) and the left upper quadrant (10.7%). Patients with RD > 1 cm on pre-treatment CT (discordant) exhibited a significantly greater risk of disease progression (HR 1.30; 95% CI 1.08–1.56; p = 0.0059).

      Conclusions

      Among patients reported to have undergone optimal cytoreduction, 40% were found to have lesions >1 cm on postoperative, pretreatment imaging. Although inflammatory changes and/or rapid tumor regrowth could account for the discordance, the impact on PFS and distribution of RD may suggest underestimation by the operating surgeon.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        • Cancer Statistics
        CA Cancer J. Clin. 2017; 67: 7-30
        • Bookman M.
        Trials with impact on clinical management: first line.
        Int. J. Gynecol. Cancer. 2009; 19 (official journal of the International Gynecological Cancer Society): S55-62
        • Winter 3rd, W.E.
        • Maxwell G.L.
        • Tian C.
        • Carlson J.W.
        • Ozols R.F.
        • Rose P.G.
        • et al.
        Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study.
        J. Clin. Oncol. 2007; 25 (Epub 2007/08/21): 3621-3627
        • Griffiths C.T.
        Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma.
        Natl. Cancer Inst. Monogr. 1975; 42: 101-104
        • Chang S.J.
        • Bristow R.E.
        • Ryu H.S.
        Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
        Ann. Surg. Oncol. 2012; 19: 4059-4067
        • Hoskins W.J.
        • McGuire W.P.
        • Brady M.F.
        • Homesley H.D.
        • Creasman W.T.
        • Berman M.
        • et al.
        The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.
        Am. J. Obstet. Gynecol. 1994; 170 (discussion 9–80): 974-979
        • Landrum L.M.
        • Java J.
        • Mathews C.A.
        • Lanneau Jr., G.S.
        • Copeland L.J.
        • Armstrong D.K.
        • et al.
        Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a gynecologic oncology group study.
        Gynecol. Oncol. 2013; 130: 12-18
        • Bristow R.E.
        • Tomacruz R.S.
        • Armstrong D.K.
        • Trimble E.L.
        • Montz F.J.
        Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
        J. Clin. Oncol. 2002; 20 (Epub 2002/03/01): 1248-1259
        • Chi D.S.
        • Eisenhauer E.L.
        • Lang J.
        • Huh J.
        • Haddad L.
        • Abu-Rustum N.R.
        • et al.
        What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?.
        Gynecol. Oncol. 2006; 103 (Epub 2006/05/23): 559-564
        • Ozols R.
        • Bundy B.
        • Greer B.
        • Fowler J.
        • Clarke-Pearson D.
        • Burger R.
        • et al.
        Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study.
        J. Clin. Oncol. 2003; 21: 3194-3200
        • Armstrong D.K.
        • Bundy B.
        • Wenzel L.
        • Huang H.Q.
        • Baergen R.
        • Lele S.
        • et al.
        Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
        N. Engl. J. Med. 2006; 354 (Epub 2006/01/06): 34-43
        • Prefontaine M.
        • Gelfand A.T.
        • Donovan J.T.
        • Powell J.L.
        Reproducibility of tumor measurements in ovarian cancer: a study of interobserver variability.
        Gynecol. Oncol. 1994; 55 (Epub 1994/10/01): 87-90
        • Chi D.S.
        • Ramirez P.T.
        • Teitcher J.B.
        • Mironov S.
        • Sarasohn D.M.
        • Iyer R.B.
        • et al.
        Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less.
        J. Clin. Oncol. 2007; 25 (Epub 2007/11/01): 4946-4951
        • Sala E.
        • Mannelli L.
        • Yamamoto K.
        • Griffin M.
        • Griffin N.
        • Grant L.
        • et al.
        The value of postoperative/preadjuvant chemotherapy computed tomography in the management of patients with ovarian cancer.
        Int. J. Gynecol. Cancer. 2011; 21 (official journal of the International Gynecological Cancer Society): 296-301
        • Burger R.A.
        • Brady M.F.
        • Bookman M.A.
        • Fleming G.F.
        • Monk B.J.
        • Huang H.
        • et al.
        Incorporation of bevacizumab in the primary treatment of ovarian cancer.
        N. Engl. J. Med. 2011; 365 (Epub 2011/12/30): 2473-2483
        • Therasse P.
        • Arbuck S.G.
        • Eisenhauer E.A.
        • Wanders J.
        • Kaplan R.S.
        • Rubinstein L.
        • et al.
        New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
        J. Natl. Cancer Inst. 2000; 92: 205-216
        • Aletti G.D.
        • Dowdy S.C.
        • Gostout B.S.
        • Jones M.B.
        • Stanhope C.R.
        • Wilson TO
        • et al.
        Aggressive surgical effort and improved survival in advanced-stage ovarian cancer.
        Obstet. Gynecol. 2006; 107: 77-85
        • Bristow R.E.
        • Montz F.J.
        • Lagasse L.D.
        • Leuchter R.S.
        • Karlan B.Y.
        Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
        Gynecol. Oncol. 1999; 72: 278-287
        • Chang S.J.
        • Bristow R.E.
        • Chi D.S.
        • Cliby W.A.
        Role of aggressive surgical cytoreduction in advanced ovarian cancer.
        J. Gynecol. Oncol. 2015; 26: 336-342
        • Colombo P.E.
        • Mourregot A.
        • Fabbro M.
        • Gutowski M.
        • Saint-Aubert B.
        • Quenet F.
        • et al.
        Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients.
        Eur. J. Surg. Oncol. 2009; 35: 135-143
        • Eisenhauer E.L.
        • Abu-Rustum N.R.
        • Sonoda Y.
        • Levine D.A.
        • Poynor E.A.
        • Aghajanian C.
        • et al.
        The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
        Gynecol. Oncol. 2006; 103: 1083-1090
        • Eisenkop S.M.
        • Spirtos N.M.
        • Friedman R.L.
        • Lin W.C.
        • Pisani A.L.
        • Perticucci S.
        Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study.
        Gynecol. Oncol. 2003; 90: 390-396
        • Petrillo M.
        • Zannoni G.F.
        • Tortorella L.
        • Pedone Anchora L.
        • Salutari V.
        • Ercoli A.
        • et al.
        Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer.
        Am. J. Obstet. Gynecol. 2014; 211 (632 e1-8)
        • Chi D.S.
        • Barlin J.N.
        • Ramirez P.T.
        • Levenback C.F.
        • Mironov S.
        • Sarasohn D.M.
        • et al.
        Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller.
        Int. J. Gynecol. Cancer: official journal of the International Gynecological Cancer Society. 2010; 20 (353-7. Epub 2010/04/09)
        • Burger I.A.
        • Goldman D.A.
        • Vargas H.A.
        • Kattan M.W.
        • Yu C.
        • Kou L.
        • et al.
        Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer.
        Gynecol. Oncol. 2015; 138: 554-559
        • Aletti G.D.
        • Dowdy S.C.
        • Podratz K.C.
        • Cliby W.A.
        Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer.
        Gynecol. Oncol. 2006; 100: 283-287
        • Schwartz L.
        • Schrot-Sanyan S.
        • Brigand C.
        • Baldauf J.J.
        • Wattiez A.
        • Akladios C.
        Impact of pelvic and para-aortic lymphadenectomy in advanced ovarian cancer after neoadjuvant chemotherapy.
        Anticancer Res. 2015; 35: 5503-5509
        • Coakley F.V.
        • Choi P.H.
        • Gougoutas C.A.
        • Pothuri B.
        • Venkatraman E.
        • Chi D.
        • et al.
        Peritoneal metastases: detection with spiral CT in patients with ovarian cancer.
        Radiology. 2002; 223: 495-499
        • de Bree E.
        • Koops W.
        • Kroger R.
        • van Ruth S.
        • Witkamp A.J.
        • Zoetmulder F.A.
        Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement.
        J. Surg. Oncol. 2004; 86: 64-73
        • Burger R.A.
        • Brady M.F.
        • Rhee J.
        • Sovak M.A.
        • Kong G.
        • Nguyen H.P.
        • et al.
        Independent radiologic review of the gynecologic oncology group study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.
        Gynecol. Oncol. 2013; 131: 21-26

      CHORUS Manuscript

      View Open Manuscript